Puma Biotechnology (PBYI) Net Income towards Common Stockholders (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$3.8 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 226.19% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.8 million (up 265.22% YoY) and the FY2025 annual result came in at $34.5 million, up 19834.29% from the prior year.
• Net Income towards Common Stockholders slipped to -$3.8 million in Q1 2026, from $16.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $20.3 million in Q3 2024 to a low of -$11.1 million in Q4 2024.
• A 5-year average of $3.1 million and a median of $2.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 1710.0% — and 2024, when it slumped 443.68%.
• Tracing PBYI's Net Income towards Common Stockholders over 5 years: stood at -$5.2 million in 2022, then jumped by 341.62% to $12.4 million in 2023, then plunged by 189.57% to -$11.1 million in 2024, then jumped by 251.26% to $16.9 million in 2025, then plunged by 122.26% to -$3.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$3.8 million (Q1 2026), $16.9 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.